ethyl 3-cyano-4-trifluoromethanesulfonyloxybenzoate | 939051-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-cyano-4-trifluoromethanesulfonyloxybenzoate
• 英文别名: 2-cyano-4-carboethoxyphenyl triflate；4-(ethoxycarbonyl)-2-cyanophenyl trifluoromethanesulfonate；ethyl 3-cvano-4-trifluoromethanesulfonyloxy-benzoate；Ethyl 3-cyano-4-trifluoromethanesulfonyloxybenzoate；ethyl 3-cyano-4-(trifluoromethylsulfonyloxy)benzoate
• CAS: 939051-02-2
• 化学式: C₁₁H₈F₃NO₅S
• 分子量: 323.249
• InChiKey: RVXCRXVPVIVIBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  ethyl 3-cyano-4-trifluoromethanesulfonyloxybenzoate 在 四(三苯基膦)钯 、 potassium fluoride dihydrate 、 水 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 3.0h， 生成 2-氰基-4-联苯羧酸
  参考文献：
  名称：

  Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5

  摘要：

  Based on SAR in the alkyne class of mGlu5 receptor negative allosteric modulators and a set of amide-based positive allosteric modulators, optimized substitution of the aryl 'b' ring was used to create substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides. Results from an mGlu5 receptor functional assay, using calcium fluorescence, revealed varying efficacies and potencies that provide evidence that subtle changes in compounds within a close structural class can have marked effects on functional activity including switches in modes of efficacy (i.e., negative to positive allosteric modulation). Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.12.110
• 作为产物：
  描述：

  4-羟基-3-碘苯甲酸乙酯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 26.5h， 生成 ethyl 3-cyano-4-trifluoromethanesulfonyloxybenzoate
  参考文献：
  名称：

  Synthesis and evaluation of 1,2,4-methyltriazines as mGluR5 antagonists

  摘要：

  在前期的研究中，我们展示了3-(取代苯乙炔基)-5-甲基[1,2,4]三嗪类类似物MPEP是谷氨酸介导的细胞内钙动员的强效拮抗剂，通过mGluR5体外效力检测。在本研究中，我们报道了六种3-(取代联苯乙炔基)-5-甲基[1,2,4]三嗪（5a–f）和五种3-(取代苯氧基苯乙炔基)-5-甲基三嗪（6a–e）的合成与评估。化合物2-(4-氟苯基)-5-[2-(5-甲基[1,2,4]三嗪-3-基)乙炔基]苯腈（5f），其IC50值为28.2 nM，是其中效力最强的类似物。

  DOI：

  10.1039/c0ob01190h

文献信息

• S1P receptor modulating compounds and use thereof
  申请人：Saha Ashis K.

  公开号：US20080064677A9

  公开（公告）日：2008-03-13

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其作为S1P受体调节剂具有活性，并使用这种化合物来治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、炎症性肠病（如克罗恩病和溃疡性结肠炎）、1型糖尿病、葡萄膜炎、牛皮癣、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behcet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• AMPA RECEPTOR POTENTIATORS
  申请人：Dominguez-Manzanares Esteban

  公开号：US20100010090A1

  公开（公告）日：2010-01-14

  The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

  本发明涉及公式（I）的化合物或其药学上可接受的盐，其对于与谷氨酸功能不足有关的疾病，如精神和神经疾病的治疗是有用的。
• S1P Receptor Modulating Compounds and Use Thereof
  申请人：Saha Ashis K.

  公开号：US20110059945A1

  公开（公告）日：2011-03-10

  The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及一般式（I）的化合物，其具有作为S1P受体调节剂的活性，以及使用这些化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物可用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫性疾病，包括全身性红斑狼疮、克罗恩病和溃疡性结肠炎、I型糖尿病、葡萄膜炎、银屑病、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• AMPA receptor potentiators
  申请人：Eli Lilly and Company

  公开号：US08097652B2

  公开（公告）日：2012-01-17

  The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其对于与谷氨酸低功能相关的疾病的治疗有用，例如精神和神经系统疾病。
• WO2008/73789
  申请人：——

  公开号：——

  公开（公告）日：——